Press Releases by "Taiho Pharmaceutical Co., Ltd."

• NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent “Yondelis® IV Infusion”
  [ Pharmaceuticals | 2015-11-26]
• Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
  [ Pharmaceuticals | 2015-11-13]
• Taiho Pharmaceutical Completes Submission of TAS-102 New Drug Application to the US Food and Drug Administration for the Treatment of Refractory Metastatic Colorectal Cancer
  [ Pharmaceuticals | 2014-12-24]
• Antitumor Agent "Abraxane®I.V. Infusion 100 mg" Approved for Additional Indication of Unresectable Pancreatic Cancer
  [ Pharmaceuticals | 2014-12-18]
• Taiho Pharmaceutical Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer – Taiho Initiates Rolling NDA Submission for TAS-102 –
  [ Pharmaceuticals | 2014-10-21]
• Phase III Clinical Trial Results of TS-1 on Metastatic Colorectal Cancer Published in Digital Version of The Lancet Oncology
  [ Pharmaceuticals | 2013-11-11]
• Announcement; Launch of 5-HT3 Receptor Antagonist Aloxi® I.V. infusion bag 0.75mg
  [ Pharmaceuticals | 2012-11-30]
• ZOSYN®, an Injectable Antibiotic Combination Product Receives an Approval for Peritonitis, Intra-abdominal Abscess, Cholecystitis, and Cholangitis
  [ Pharmaceuticals | 2012-09-28]
• Clinical Trial (JASPAC 01) of TS-1 for Resected Pancreatic Cancer
  [ Pharmaceuticals | 2012-09-18]
• Results of a Phase II Clinical Trial for the Novel Antitumor Agent TAS-102 Posted on the Electronic Edition of The Lancet Oncology
  [ Pharmaceuticals | 2012-08-28]
• Taiho and Faes Farma (Spain) Enter into a License Agreement on Anti-Allergy Agent
  [ Pharmaceuticals | 2012-07-24]
• Launch of Histamine H2 Receptor Antagonist PROTECADIN® OD Tablets (Orally Disintegrating Tablet)
  [ Pharmaceuticals | 2012-06-22]
• Phase III Clinical Trial (CATS TRIAL) for Non-small-cell Lung Cancer Non-inferiority of TS-1 + Cisplatin Treatment Verified Presented to the American Society of Clinical Oncology (ASCO)
  [ Pharmaceuticals | 2012-06-06]
• Taiho Pharmaceutical Announces the Start of a Global Phase III Clinical Trial in Metastatic Colorectal Cancer with the Novel Antitumor Agent TAS-102
  [ Pharmaceuticals | 2012-05-31]
• Anti-Cancer Drug Teysuno® has been launched in the United Kingdom.
  [ Pharmaceuticals | 2012-04-11]
• Taiho Pharmaceutical’s Anticancer Agent TS-1 Approved for Market in Hong Kong
  [ Pharmaceuticals | 2012-04-11]
• Anti-Cancer Drug TeysunoTM has been launched in Sweden, Denmark, Norway and Finland
  [ Pharmaceuticals | 2012-03-21]
• Taiho Pharmaceutical Co., Ltd. and Nordic Group BV have launched Anti-Cancer Drug TeysunoTM in Sweden, Denmark, Norway and Finland
  [ Pharmaceuticals | 2012-03-21]
• Taiho Pharmaceutical’s Anticancer Agent TS-1 Approved for Market in Thailand
  [ Pharmaceuticals | 2012-03-21]
• Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis
  [ Pharmaceuticals | 2012-03-09]

Most Popular: "Taiho Pharmaceutical Co., Ltd."